Status:
RECRUITING
BIOlogics in Severe Nasal POlyposis SurvEy
Lead Sponsor:
University Hospital, Lille
Conditions:
Chronic Rhinosinusitis With Nasal Polyps
Eligibility:
All Genders
18+ years
Brief Summary
With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So fa...
Eligibility Criteria
Inclusion
- Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval
Exclusion
- Oral corticotherapy in the previous month;
- Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months apart from ongoing biotherapies for severe asthma;
- Hypersensitivity to humanized antibodies ;
- Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;
- Pregnant or breast-feeding women;
- Patient without social coverage
Key Trial Info
Start Date :
February 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05228041
Start Date
February 10 2022
End Date
July 1 2027
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037